newsfilter
← Latest News
Business Wire·

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

No safety concerns identified by independent data and safety monitoring board, which recommends continuation of study without any modifications Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology